Literature DB >> 22476753

Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome.

George A Poultsides1, Fei Bao, Elliot L Servais, Tina Hernandez-Boussard, Ronald P DeMatteo, Peter J Allen, Yuman Fong, Nancy E Kemeny, Leonard B Saltz, David S Klimstra, William R Jarnagin, Jinru Shia, Michael I D'Angelica.   

Abstract

BACKGROUND: Pathologic response to preoperative chemotherapy for colorectal liver metastases (CLM) is associated with survival after hepatectomy. Histologically, dominant response patterns include fibrosis, necrosis and/or acellular mucin, but some of these changes can appear without previous chemotherapy and their individual correlation with outcome is unknown.
METHODS: Pathology slides from patients who underwent CLM resection (irrespective of preoperative chemotherapy status) were rereviewed by a blinded pathologist. Pathologic response was recorded as the summation of percentage necrosis, fibrosis and acellular mucin. Associations between pathologic response, its components, preoperative chemotherapy, and survival were analyzed.
RESULTS: Pathology slides were rereviewed in 366 patients undergoing CLM resection from 2003 to 2007. Preoperative chemotherapy was administered in 249 (68 %) patients, who, when compared to no preoperative chemotherapy patients, had higher rates of overall pathologic response (57 vs. 46 %, P < .01), fibrosis (21 vs. 12 %, P < .01) and acellular mucin (6 vs. 3 %, P = .05) but similar rates of necrosis (30 vs. 31 %, P = .30). In patients receiving preoperative chemotherapy, overall pathologic response ≥ 75 % (5 year, 83 vs. 47 %, P < .01) and fibrosis ≥ 40 % (5 year, 87 vs. 51 %, P < .01) independently correlated with disease-specific survival after hepatectomy. Preoperative hepatic artery infusion chemotherapy (P = .04) and bevacizumab (P = .05) were marginally associated with overall pathologic response and fibrosis, respectively.
CONCLUSIONS: Fibrosis is the predominant chemotherapy-related pathologic alteration driving the association of treatment response with survival after CLM resection. Necrosis in CLM is not related to chemotherapy or outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476753     DOI: 10.1245/s10434-012-2335-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Late gadolinium MRI enhancement of colorectal liver metastases is associated with overall survival among nonsurgical patients.

Authors:  Helen M C Cheung; Jin K Kim; John Hudson; Natalie Coburn; Paul J Karanicolas; Calvin Law; Laurent Milot
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

3.  Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour.

Authors:  Mathilde Wagner; Maxime Ronot; Sabrina Doblas; Céline Giraudeau; Bernard Van Beers; Jacques Belghiti; Valérie Paradis; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2015-05-02       Impact factor: 5.315

Review 4.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

5.  Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy.

Authors:  M L Gómez Dorronsoro; R Vera; L Ortega; C Plaza; R Miquel; M García; E Díaz; M R Ortiz; J Pérez; C Hörndler; C Villar; J Antúnez; S Pereira; F López-Rios; R González-Cámpora
Journal:  Clin Transl Oncol       Date:  2013-09-10       Impact factor: 3.405

6.  Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.

Authors:  R Vera; M Gomez Dorronsoro; S Lopez-Ben; A Viudez; B Queralt; I Hernandez; M R Ortiz-Duran; C Zazpe; J Soriano; I Amat; J Herrera Cabezón; E Diaz; A Codina-Barreras; X Hernandez-Yagüe; A Quera; J Figueras
Journal:  Clin Transl Oncol       Date:  2013-12-12       Impact factor: 3.405

7.  Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer.

Authors:  Amber L Simpson; Alexandre Doussot; John M Creasy; Lauryn B Adams; Peter J Allen; Ronald P DeMatteo; Mithat Gönen; Nancy E Kemeny; T Peter Kingham; Jinru Shia; William R Jarnagin; Richard K G Do; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

8.  Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes.

Authors:  Yujiro Nishioka; Junichi Shindoh; Ryuji Yoshioka; Wataru Gonoi; Hiroyuki Abe; Naoki Okura; Shuntaro Yoshida; Masaru Oba; Masaji Hashimoto; Goro Watanabe; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

9.  Management of potentially resectable colorectal cancer liver metastases.

Authors:  Fausto Meriggi; Paola Bertocchi; Alberto Zaniboni
Journal:  World J Gastrointest Surg       Date:  2013-05-27

10.  Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases.

Authors:  Junichi Shindoh; Ching-Wei D Tzeng; Thomas A Aloia; Steven A Curley; Giuseppe Zimmitti; Steven H Wei; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2013-02-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.